Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation

Keyphrases

• Tumor 100%
• Tumor Immunity 100%
• DNA Methylation (DNAm) 100%
• Adaptive Antitumor Immunity 100%
• Genetically Engineered Mouse Models 66%
• Immune Control 66%
• Stimulator of Interferon Genes (STING) 66%
• Decitabine 66%
• Cell-cell Communication 33%
• Tumor Growth 33%
• Gene Editing 33%
• Gene Expression 33%
• Tumor-infiltrating Immune Cells 33%
• Breast Cancer 33%
• Cancer Cells 33%
• Malignancy 33%
• CD8+ T Cells 33%
• Breast Tumor 33%
• Genome-wide Studies 33%
• Myeloid-derived Suppressor Cells 33%
• Cell-intrinsic 33%
• Melanocytic Tumor 33%
• Single-cell RNA Sequencing (scRNA-seq) 33%
• Evade 33%
• Immunosurveillance 33%
• Immune-related Genes 33%
• Tumor-related Genes 33%
• Pyroptosis 33%
• Tumor-infiltrating Lymphocytes 33%
• Inflammatory Cell Death 33%
• Early Tumor 33%
• Innate Immune Genes 33%
• Immunity Genes 33%
• Early Tumorigenesis 33%
• Necroptosis-related Genes 33%

Immunology and Microbiology

• Mouse Model 100%
• Genetically Engineered Mouse Strain 100%
• DNA Methylation 100%
• interferon 50%
• Gene Expression 50%
• Low Drug Dose 50%
• Immunocompetent Cell 50%
• Cell Death 50%
• Cytotoxic T-Cell 50%
• Cancer Cell 50%
• Precursor 50%
• RNA Sequence 50%
• Inflammatory Cell 50%
• Interferon-Stimulated Gene 50%
• Immunosurveillance 50%
• Cell Communication 50%
• Gene Editing 50%
• Pyroptosis 50%
• Necroptosis 50%
• Tumor-Infiltrating Lymphocytes 50%
• Tumor Gene 50%
• Myeloid Suppressor Cell 50%